Who is sponsoring NCT04164368?

NCT04164368 is sponsored by Fudan University.

What drugs are being tested in NCT04164368?

Interventions in NCT04164368: Lenalidomide combined with R-CHOP.

What condition does NCT04164368 study?

NCT04164368 studies Double Expressor Lymphoma.

Is NCT04164368 still recruiting?

NCT04164368 is currently completed. Last updated 13 May 2024.

Last reviewed 2024-05-13 · How we verify

NCT04164368

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

Completed Phase 2 Last updated 13 May 2024

What this trial tests

Phase 2 trial testing Lenalidomide combined with R-CHOP in Double Expressor Lymphoma in 67 participants. Completed in 30 August 2023.

Timeline

22 October 2019

Primary endpoint
9 August 2021

30 August 2023

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	22 October 2019
Primary completion	9 August 2021
Estimated completion	30 August 2023
Sites	1 location across China

Drugs / interventions tested

Lenalidomide combined with R-CHOP — full drug profile →

Conditions studied

Double Expressor Lymphoma — all drugs for Double Expressor Lymphoma →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Double Expressor Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this phase II study, the investigators are aiming to explore lenalidomide combined with R-CHOP (R2-CHOP) in newly diagnosed double-expressor Diffuse Large B-Cell Lymphoma patients (DLBCL)

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy.
de Jonge AV, Mutis T, Roemer MGM, Scheijen B, et al · · 2020 · cited 15× · PMID 33092116 · DOI 10.3390/cancers12103052
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.
Danilov AV, Magagnoli M, Matasar MJ. · · 2022 · cited 10× · PMID 35305092 · DOI 10.1093/oncolo/oyab004
Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial.
Liu Y, Zhang Q, Lv F, Liu X, et al · · 2025 · cited 1× · PMID 40000615 · DOI 10.1038/s41408-025-01229-5

Verify or expand the search:

Other recruiting trials for Double Expressor Lymphoma

Currently open trials in the same condition.

NCT04479267 — Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma · Phase 2 · active not recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04164368 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 13 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04164368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing